liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock.
Linköpings universitet, Institutionen för klinisk och experimentell medicin, Infektionsmedicin. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Hjärt- och Medicincentrum, Infektionskliniken i Östergötland.
Clinical microbiology — Karolinska Institutet, Karolinska University Hospital, Stockholm.
Athens University Medical School, Athens, Greece.
2011 (Engelska)Ingår i: Current Infectious Disease Reports, ISSN 1523-3847, E-ISSN 1534-3146, Vol. 13, nr 5, s. 416-425Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

In the 80s and 90s, increasing antibiotic resistance was met by the introduction of new effective agents with broader antibacterial spectra for the empirical treatment of severe infections. In recent years, however, few novel antimicrobials have been developed, and this has critically weakened our strength in the fight against resistant bacteria, especially Gram-negative bacilli. It has been well proven that mortality increases if initial empirical antibiotic treatment for severe infection is inappropriate due to resistance of the pathogen. Physicians are already faced with the increasing challenge of untreatable or almost untreatable Gram-negative infections due to antibiotic resistance. Empirical treatment with broader spectra and high antibiotic pressure both in- and outside hospital is the driving force behind resistance. Since new efficient drugs against Gram-negative bacilli will not be available for some time, the best we can do to stop infections caused by multidrug-resistant bacteria is to improve infection control and choice of antibiotics, which should be based on surveillance of local antibiotic consumption and resistance. We must learn more about the revived antibacterial agents colistin and fosfomycin, and the few next generation Gram-negative antibiotics that have been developed. The aim of this review is to give an update on present therapeutic options in the fight against multidrug-resistant Gram-negative bacteria.

Ort, förlag, år, upplaga, sidor
Springer, 2011. Vol. 13, nr 5, s. 416-425
Nyckelord [en]
Resistant Gram Negative Bacilli; MDR; PDR; XDR; Colistin; Tigecycline; Fosfomycin; Neoglycoside; β-lactamase inhibitors Extended-spectrum beta-lactamase; Plasmid-mediated quinolone resistance; 16S rRNA methylase; Carbapenemase; NXL-104; BAL30072; Temocillin; ACHN-490; Multi-drug resistance; Prevalence of resistance
Nationell ämneskategori
Infektionsmedicin
Identifikatorer
URN: urn:nbn:se:liu:diva-70418DOI: 10.1007/s11908-011-0200-1PubMedID: 21800232OAI: oai:DiVA.org:liu-70418DiVA, id: diva2:439188
Tillgänglig från: 2011-09-06 Skapad: 2011-09-06 Senast uppdaterad: 2017-12-08Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Person

Hanberger, Håkan

Sök vidare i DiVA

Av författaren/redaktören
Hanberger, Håkan
Av organisationen
InfektionsmedicinHälsouniversitetetInfektionskliniken i Östergötland
I samma tidskrift
Current Infectious Disease Reports
Infektionsmedicin

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 341 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf